Medicinal cannabis may be a
a promising treatment for children
and young adults with treatment
resistant epilepsy and it is generally
well-tolerated in doses up to 25mg/
kg/day, according to a preliminary
study presented to the annual
meeting of the American Epilepsy
Society this week.
The authors concluded that these
initial results from an uncontrolled
study should now be further tested
in randomised controlled trials.The above article was sent to subscribers in Pharmacy Daily's issue from 10 Dec 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 10 Dec 15
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.